DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for osteoarthritis — screening already-approved drugs against its 45-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOsteoarthritis maps to a 45-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for osteoarthritis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
FTO alpha-ketoglutarate dependent dioxygenase (FTO) — FTO is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3-hydroxypyridin-2-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4IE5 · 1.95 Å · ligand N-[(3-hydroxypyridin-2-yl)carbonyl]glycine (MD6). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Birkhäuser Basel eBooks · 2002 · 2 citations
Genetics and osteoarthritis
AbstractGenetic approaches complement other approaches for gaining insights about the pathogenesis of osteoarthritis. Genetic mapping of simple Mendelian skeletal diseases can identify genes that participate in normal joint homeostatic pathways. Genetic studies in cohorts of patients having common forms of osteoarthritis will be more challenging, but may also identify genes that contribute to osteoarthritis predisposition and/or disease progression. Employing the entire human transcriptome to study changes in gene expression between normal and diseased tissues, or cells, can identify other participants in these complex pathways. Finally, naturally occurring mutations, or induced genetic variations, in other organisms can be used to model human disease phenotypes and further dissect the processes responsible for disease pathogenesis.
The present and progress of common drug therapy in treating osteoarthritis
AbstractOsteoarthritis (OA) is an very common disease among elderly people but still no effective therapy to cure. Drug therapy-as the first line treatment in OA has been proved valuable in releasing the clinical symptom and slow down the progress of the disease. Along with constantly use of drug therapy, the comprehension of the effect and side effect of drugsaregrowing. This article reviews the present and outlook of drug therapy, hopefully it can provide theoretical basis for clinical treatment of OA.
Key words:
Osteoarthritis; Drug therapy; Intra-articular therapy
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
